Clinical Trial: Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06945458) titled 'Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)' on April 09.

Brief Summary: This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: KT-621

Oral drug

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Kymera Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....